Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 7/2007

01.07.2007 | Original Paper

Transforming growth factor-β downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma

verfasst von: Cheryn Song, Sun-Young Jun, Jun-Hyuk Hong, Hanjong Ahn

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated signal transducer and activator of transcription-5 (STAT5) activation status in renal cell carcinoma (RCC) and the role of transforming growth factor-β (TGF-β) in the process.

Methods

Twenty normal and RCC tissues were obtained from radical nephrectomy specimens for the assessment of expressions of phosphorylated STAT5 (p-STAT5) and TGF-β1 (Western blot) and for localization and assessment of their relationship (immunohistochemical and immunofluorescence stains). By using four RCC cell lines and four primary cultured cells, the effect of TGF-β1 and/or interleukin-2 (IL-2) on the expressions of p-STAT5 were analyzed.

Results

In RCC samples, expression of p-STAT5 was significantly reduced while expression of TGF-β was enhanced compared with normal kidney tissues (P < 0.001 and P = 0.003, respectively). P-STAT5 was observed almost exclusively in the nuclei of normal kidney tissues while TGF-β was identified in the cytoplasm of cells of both tissues reflecting the Western results. In both RCC cell lines and cells from primary cultures, treatment with TGF-β or antibody did not significantly alter STAT5 activation. However, TGF-β significantly suppressed IL-2-induced STAT5 activation, whereas anti-TGF-β antibodies enhanced IL-2-induced STAT5 further.

Conclusions

STAT5 activation is suppressed in RCC compared with normal renal parenchyma. It may be attributed to the RCC-derived TGF-β which also interferes with IL-2-induced STAT5 pathway activation.
Literatur
Zurück zum Zitat Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT (1993) Anti-TGFβ antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen cell natural killer activity. J Clin Invest 92:2569–2576PubMedCrossRef Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT (1993) Anti-TGFβ antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen cell natural killer activity. J Clin Invest 92:2569–2576PubMedCrossRef
Zurück zum Zitat Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E (2001) Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15:1923–1931PubMed Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E (2001) Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15:1923–1931PubMed
Zurück zum Zitat Bright JJ, Kerr LD, Sriram S (1997) TGF-β inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat5 in T lymphocytes. J Immunol 159:175–183PubMed Bright JJ, Kerr LD, Sriram S (1997) TGF-β inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat5 in T lymphocytes. J Immunol 159:175–183PubMed
Zurück zum Zitat Buitenhuis M, Coffer PJ, Koenderman L (2004) Signal transducer and activator of transcription 5 (STAT5). Int J Biochem Cell Biol 36:2120–2124PubMedCrossRef Buitenhuis M, Coffer PJ, Koenderman L (2004) Signal transducer and activator of transcription 5 (STAT5). Int J Biochem Cell Biol 36:2120–2124PubMedCrossRef
Zurück zum Zitat Campbell JD, Cook G, Robertson SE, Fraser A, Boyd KS, Gracie JA, Franklin IM (2001) Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF-β is reversed by IL-15. J Immunol 167:553–561PubMed Campbell JD, Cook G, Robertson SE, Fraser A, Boyd KS, Gracie JA, Franklin IM (2001) Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF-β is reversed by IL-15. J Immunol 167:553–561PubMed
Zurück zum Zitat Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC (2003) Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 89:344–349PubMedCrossRef Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC (2003) Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 89:344–349PubMedCrossRef
Zurück zum Zitat Junker U, Haufe CC, Nuske K, Rebstock K, Steiner T, Wunderlich H, Junker K, Reinhold D (2000) Elevated plasma TGF-β1 in renal diseases: cause or consequence? Cytokine 12:1084–1091PubMedCrossRef Junker U, Haufe CC, Nuske K, Rebstock K, Steiner T, Wunderlich H, Junker K, Reinhold D (2000) Elevated plasma TGF-β1 in renal diseases: cause or consequence? Cytokine 12:1084–1091PubMedCrossRef
Zurück zum Zitat Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64:4774–4782PubMedCrossRef Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64:4774–4782PubMedCrossRef
Zurück zum Zitat Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT (2005) Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11:5863–5868PubMedCrossRef Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT (2005) Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11:5863–5868PubMedCrossRef
Zurück zum Zitat Mitropoulos D, Kiroudi A, Christelli E, Serafetinidis E, Zervas A, Anastasiou I, Dimopoulos C (2004) Expression of transforming growth factor β in renal cell carcinoma and matched non-involved renal tissue. Urol Res 32:317–322PubMedCrossRef Mitropoulos D, Kiroudi A, Christelli E, Serafetinidis E, Zervas A, Anastasiou I, Dimopoulos C (2004) Expression of transforming growth factor β in renal cell carcinoma and matched non-involved renal tissue. Urol Res 32:317–322PubMedCrossRef
Zurück zum Zitat Miyajima A, Asano T, Seta K, Asano T, Kakoi N, Hayakawa M (2003) Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology 61:1072–1077PubMedCrossRef Miyajima A, Asano T, Seta K, Asano T, Kakoi N, Hayakawa M (2003) Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology 61:1072–1077PubMedCrossRef
Zurück zum Zitat Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H (2004) Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053–2060PubMedCrossRef Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H (2004) Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053–2060PubMedCrossRef
Zurück zum Zitat Ramp U, Jaquet K, Reinecke P, Nitsch T, Gabbert HE, Gerharz CD (1997) Acquisition of TGF-β1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest 76:739–749PubMed Ramp U, Jaquet K, Reinecke P, Nitsch T, Gabbert HE, Gerharz CD (1997) Acquisition of TGF-β1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest 76:739–749PubMed
Zurück zum Zitat Sudarshan C, Galon J, Zhou Y, O’Shea JJ (1999) TGF-β does not inhibit IL-12- and IL-2-induced activation of Janus kinases and STATs. J Immunol 162:2974–2981PubMed Sudarshan C, Galon J, Zhou Y, O’Shea JJ (1999) TGF-β does not inhibit IL-12- and IL-2-induced activation of Janus kinases and STATs. J Immunol 162:2974–2981PubMed
Zurück zum Zitat Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H (2005) Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24:746–760PubMedCrossRef Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H (2005) Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24:746–760PubMedCrossRef
Zurück zum Zitat Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BK, Matsuoka M, Yamaguchi K, Takatsuki K, Kamihira S, White JD, Leonard WJ, Waldmann T, Franchini G (1997) Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA 94:13897–13902PubMedCrossRef Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BK, Matsuoka M, Yamaguchi K, Takatsuki K, Kamihira S, White JD, Leonard WJ, Waldmann T, Franchini G (1997) Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA 94:13897–13902PubMedCrossRef
Metadaten
Titel
Transforming growth factor-β downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma
verfasst von
Cheryn Song
Sun-Young Jun
Jun-Hyuk Hong
Hanjong Ahn
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-007-0192-2

Weitere Artikel der Ausgabe 7/2007

Journal of Cancer Research and Clinical Oncology 7/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.